Sign In
Buy MMSI
$67.27
+0.770 (+1.16%)
At Close: Jun 23, 2026
PerkinElmer (PKI) Q3 Earnings Top, Revenues Decline Y/Y
03:39pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
PerkinElmer's (PKI) third-quarter results benefit from the solid performance of the Discover & Analytics Solutions business, which was more than offset by lower COVID-related sales.
Shockwave Medical (SWAV) Beats on Q3 Earnings & Revenues
03:32pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and expansion in gross margin.
PacBio's (PACB) Q3 Earnings Top Estimates, Revenues Lag
03:00pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
PacBio (PACB) witnesses strength in Service and other revenues, along with robust consumable sales, in the third quarter.
Bruker (BRKR) Q3 Earnings Beat Estimates, '22 Sales View Down
02:24pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Despite ongoing macroeconomic headwinds, Bruker (BRKR) registers strong demand for differentiated high-value scientific instruments and life science solutions.
Accuray's (ARAY) Q1 Earnings and Revenues Lag Estimates
04:51pm, Thursday, 03'rd Nov 2022 Zacks Investment Research
Despite solid product demand, Accuray (ARAY) reports an overall soft Q1 performance.
Myriad Genetics (MYGN) Q3 Earnings Miss, Gross Margin Falls
03:59pm, Thursday, 03'rd Nov 2022 Zacks Investment Research
Myriad Genetics (MYGN) hereditary cancer testing volume returns to growth in the third quarter. GeneSight comes up with yet another strong performance.
AmerisourceBergen (ABC) Q4 Earnings & Revenues Top Estimates
03:52pm, Thursday, 03'rd Nov 2022 Zacks Investment Research
AmerisourceBergen's (ABC) fiscal fourth-quarter 2022 results benefit from segmental growth.
Nevro (NVRO) Q3 Earnings Beat Estimates, 2022 View Revised
02:44pm, Thursday, 03'rd Nov 2022 Zacks Investment Research
Nevro's (NVRO) worldwide revenues improved on a year-over-year basis in Q3, partly owing to robust domestic performance.
QuidelOrtho (QDEL) Q3 Earnings Top Estimates, 2022 View Revised
02:19pm, Thursday, 03'rd Nov 2022 Zacks Investment Research
QuidelOrtho's (QDEL) robust results in POC and Donor Screening product lines drives its third-quarter 2022 top line.
Summary Notice to Current Merit Medical Systems, Inc. Stockholders of Derivative Action and Settlement Hearing
08:05pm, Wednesday, 02'nd Nov 2022 GlobeNewswire Inc.
SALT LAKE CITY, Nov. 02, 2022 (GLOBE NEWSWIRE) -- TO: ALL OWNERS OF MERIT MEDICAL SYSTEMS, INC. (“MERIT” OR THE “COMPANY”) COMMON STOCK AS OF AUGUST 17, 2022 (“CURRENT MERIT STOCKHOLDERS�
Charles River (CRL) Q3 Earnings Top Estimates, Margins Dip
03:37pm, Wednesday, 02'nd Nov 2022 Zacks Investment Research
Headwinds associated with foreign exchange due to the strengthening of the U.S. dollar and interest expense due to a rising interest rate environment increase concerns for Charles River (CRL).
Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Falls
03:34pm, Wednesday, 02'nd Nov 2022 Zacks Investment Research
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions barring S.E.T. and "Other" record year-over-year sales growth at CER.
CVS Health (CVS) Q3 Earnings Surpass Estimates, View Up
03:13pm, Wednesday, 02'nd Nov 2022 Zacks Investment Research
Robust sales growth across all three operating segments drive CVS Health's (CVS) top line.
Hologic (HOLX) Q4 Earnings Beat Estimates, Margins Down
02:30pm, Wednesday, 02'nd Nov 2022 Zacks Investment Research
Lower sales of COVID-19 assays and supply chain challenges drag Hologic's (HOLX) top line down.
Catalent (CTLT) Q1 Earnings Lag Estimates, FY23 View Cut
05:11pm, Tuesday, 01'st Nov 2022 Zacks Investment Research
Catalent (CTLT) records robust first-quarter fiscal 2023 results of its Pharma and Consumer Health segment despite overall soft performance.
